ES2638074T3 - Carbamatos para utilizar en el síndrome de piernas inquietas - Google Patents

Carbamatos para utilizar en el síndrome de piernas inquietas Download PDF

Info

Publication number
ES2638074T3
ES2638074T3 ES11801094.1T ES11801094T ES2638074T3 ES 2638074 T3 ES2638074 T3 ES 2638074T3 ES 11801094 T ES11801094 T ES 11801094T ES 2638074 T3 ES2638074 T3 ES 2638074T3
Authority
ES
Spain
Prior art keywords
compound
restless legs
compounds
legs syndrome
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11801094.1T
Other languages
English (en)
Spanish (es)
Inventor
Susan Marie Melnick
Duncan Paul Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Application granted granted Critical
Publication of ES2638074T3 publication Critical patent/ES2638074T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES11801094.1T 2010-06-30 2011-06-27 Carbamatos para utilizar en el síndrome de piernas inquietas Active ES2638074T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US827529 2010-06-30
US12/827,529 US8623913B2 (en) 2010-06-30 2010-06-30 Methods for treating restless legs syndrome
PCT/KR2011/004677 WO2012002688A2 (en) 2010-06-30 2011-06-27 Methods of treating restless legs syndrome

Publications (1)

Publication Number Publication Date
ES2638074T3 true ES2638074T3 (es) 2017-10-18

Family

ID=45400169

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11801094.1T Active ES2638074T3 (es) 2010-06-30 2011-06-27 Carbamatos para utilizar en el síndrome de piernas inquietas

Country Status (8)

Country Link
US (1) US8623913B2 (enExample)
EP (1) EP2588099B1 (enExample)
JP (1) JP5921539B2 (enExample)
KR (1) KR101785072B1 (enExample)
CN (1) CN103025326B (enExample)
CA (1) CA2801243C (enExample)
ES (1) ES2638074T3 (enExample)
WO (1) WO2012002688A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2435403T3 (es) 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
KR102173587B1 (ko) 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
MX350745B (es) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
GB201221329D0 (en) 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
US9359290B2 (en) 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy
KR102309836B1 (ko) 2013-07-18 2021-10-12 에스케이바이오팜 주식회사 비만의 치료
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
ES2970887T3 (es) 2016-09-06 2024-05-31 Axsome Malta Ltd Forma de solvato de carbamato de (R)-2-amino-3-fenilpropilo
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
CN109789111B (zh) 2016-09-21 2021-11-16 埃维克辛公司 药物组合物
EP4316592A3 (en) 2016-10-06 2024-05-01 Axsome Malta Ltd. Carbamoyl phenylalaninol compounds and uses thereof
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
KR102643275B1 (ko) 2017-07-31 2024-03-04 재즈 파마슈티칼즈 아일랜드 리미티드 카바모일 페닐알라니놀 유사체 및 이의 용도
US11283085B1 (en) 2020-03-06 2022-03-22 Bloom Energy Corporation Low VOC ink compositions and methods of forming fuel cell system components using the same
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11515543B1 (en) 2020-06-03 2022-11-29 Bloom Energy Corporation Aqueous fuel cell system component ink compositions and methods of forming fuel cell system components using the same
KR20260033050A (ko) 2023-06-29 2026-03-10 액섬 테라퓨틱스, 인크. 수유 여성에게 솔리암페톨을 투여하는 방법
US12201783B1 (en) * 2023-09-05 2025-01-21 Steven F Pichette Use of blue-light filtering eyeglasses for treatment of restless legs syndrome

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
IT1275903B1 (it) 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
EP0873308B1 (en) 1996-10-10 2002-01-02 SK Corporation O-carbamoyl-phenylalaninol compounds and their pharmaceutically useful salts
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
WO1999055674A1 (en) 1998-04-28 1999-11-04 Dainippon Pharmaceutical Co., Ltd. 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
US20010029262A1 (en) 1998-06-29 2001-10-11 Sethi Kapil Dev Method of treatment or prophylaxis
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
US20010034320A1 (en) 2000-01-18 2001-10-25 Hans-Michael Brecht NK1-receptor antagonists for treating restless legs syndrome
WO2002050071A1 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
WO2002067922A1 (en) 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in the treatment of pain
CN1262272C (zh) * 2001-02-27 2006-07-05 奥索-麦克尼尔药品公司 用于预防或治疗运动障碍的氨基甲酸酯化合物
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
JP2004537526A (ja) 2001-06-12 2004-12-16 メルク エンド カムパニー インコーポレーテッド 片頭痛の治療又は予防用nr2b受容体拮抗薬
US20040115263A1 (en) * 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
JP2006502180A (ja) 2002-09-20 2006-01-19 ファイザー株式会社 5−ht4レセプターモジュレーターとしてのn−置換されたピペリジニル−イミダゾピリジン化合物
BRPI0409592A (pt) 2003-04-21 2006-05-02 Pfizer compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3
UA86204C2 (uk) 2003-09-03 2009-04-10 Пфайзер Инк. Сполуки бензімідазолону, які мають 5-нт4 рецепторну агоністичну активність
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
CA2587481A1 (en) 2004-10-28 2006-05-11 Sk Corporation Phenylalkylamino carbamates adjunctive therapy for depression
GEP20105053B (en) 2005-04-08 2010-07-26 Pfizer Prod Inc Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
ES2435403T3 (es) * 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
CA2673487A1 (en) * 2006-10-13 2008-04-24 Janssen Pharmaceutica Nv Phenylalkylamino carbamate compositions
US7377267B2 (en) * 2006-10-30 2008-05-27 Ford Global Technologies, Llc Injection strategy to maximize efficiency in gaseous engine
CN101317949A (zh) * 2008-07-15 2008-12-10 洛阳梓生科技开发有限公司 一种补血调经养血柔肝胶囊的制作方法
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
KR102173587B1 (ko) 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법

Also Published As

Publication number Publication date
JP5921539B2 (ja) 2016-05-24
CA2801243C (en) 2019-01-15
US20120004301A1 (en) 2012-01-05
CN103025326A (zh) 2013-04-03
CA2801243A1 (en) 2012-01-05
US8623913B2 (en) 2014-01-07
JP2013531008A (ja) 2013-08-01
KR20130087384A (ko) 2013-08-06
WO2012002688A3 (en) 2012-04-26
HK1178796A1 (en) 2013-09-19
WO2012002688A2 (en) 2012-01-05
EP2588099A2 (en) 2013-05-08
CN103025326B (zh) 2015-07-29
EP2588099B1 (en) 2017-05-24
KR101785072B1 (ko) 2017-10-12
EP2588099A4 (en) 2013-12-25

Similar Documents

Publication Publication Date Title
ES2638074T3 (es) Carbamatos para utilizar en el síndrome de piernas inquietas
ES2743153T3 (es) Métodos para tratar el síndrome de fibromialgia
ES2927675T3 (es) Tratamiento de la cataplexia
ES2447295T3 (es) Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
ES2654615T3 (es) Compuestos de carbamato para el tratamiento del trastorno bipolar
ES2812586T3 (es) Tratamiento para la obesidad
ES2853730T3 (es) Composiciones para tratar la adicción a las drogas y mejorar el comportamiento relacionado con la adicción
ES2435403T3 (es) Tratamiento de trastornos del sueño y vigilia
HK1178796B (en) Methods of treating restless legs syndrome
HK1219236B (zh) 氨基甲酸酯化合物在制备治疗猝倒的药物中的应用